Literature DB >> 1512691

Pilot study comparing the salivary cationic protein concentrations in healthy adults and AIDS patients: correlation with antifungal activity.

K Lal1, J J Pollock, R P Santarpia, H M Heller, H W Kaufman, J Fuhrer, R T Steigbigel.   

Abstract

This investigation compared the salivary cationic protein concentrations of 12 healthy adult controls with those of 12 hospitalized patients with AIDS. Salivas were quantified by capillary electrophoresis using purified cationic protein standards. In parotid saliva, histidine-rich polypeptides (HRPs) 1-6, histatin 6, and lysozyme concentrations were determined. In addition to these eight cationic proteins, submandibular-sublingual saliva was also quantified for histatin 2 and the histatin 2 degradation product. When comparisons were made on the basis of individual proteins, the HRP-histatin concentrations in the AIDS patients showed either statistically significant decreases or a decreasing trend compared with healthy adult controls. When HRP-histatin concentrations were summed for each patient, there were statistically significant differences between the healthy adult controls and the individuals with AIDS in both parotid and submandibular-sublingual salivas. Closer examination revealed that some individuals with AIDS had HRP-histatin concentrations that fell within the normal range of the healthy adult controls. For these individuals, lower than expected salivary antifungal values were obtained. Either decreasing histidine-rich protein concentrations and/or an inability of these proteins in saliva to interact with Candida albicans may contribute to the defective salivary antifungal activity seen in AIDS patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512691

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  14 in total

1.  Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5.

Authors:  D M Rothstein; P Spacciapoli; L T Tran; T Xu; F D Roberts; M Dalla Serra; D K Buxton; F G Oppenheim; P Friden
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Further characterization of human salivary anticandidal activities in a human immunodeficiency virus-positive cohort by use of microassays.

Authors:  A L Lin; Q Shi; D A Johnson; T F Patterson; M G Rinaldi; C K Yeh
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  Studies of the mechanism of human salivary histatin-5 candidacidal activity with histatin-5 variants and azole-sensitive and -resistant Candida species.

Authors:  H Tsai; L A Bobek
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 4.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts.

Authors:  Habtom H Habte; Corena de Beer; Zoë E Lotz; Paul Roux; Anwar S Mall
Journal:  Virol J       Date:  2010-10-14       Impact factor: 4.099

6.  Differentially expressed proteins in derivatives of Candida albicans displaying a stable histatin 3-resistant phenotype.

Authors:  Deirdre H Fitzgerald-Hughes; David C Coleman; Brian C O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

7.  Susceptibility of Candida dubliniensis to salivary histatin 3.

Authors:  Deirdre H Fitzgerald; David C Coleman; Brian C O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Cooperation of salivary protein histatin 3 with heat shock cognate protein 70 relative to the G1/S transition in human gingival fibroblasts.

Authors:  Yasuhiro Imamura; Yoshihisa Fujigaki; Yuriko Oomori; Syuhei Usui; Pao-Li Wang
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

9.  Impaired Histatin-5 Levels and Salivary Antimicrobial Activity against C. albicans in HIV Infected Individuals.

Authors:  Shariq A Khan; Paul L Fidel; Awdah Al Thunayyan; Sharon Varlotta; Timothy F Meiller; Mary Ann Jabra-Rizk
Journal:  J AIDS Clin Res       Date:  2013-03-05

10.  The novel Candida albicans transporter Dur31 Is a multi-stage pathogenicity factor.

Authors:  François L Mayer; Duncan Wilson; Ilse D Jacobsen; Pedro Miramón; Katharina Große; Bernhard Hube
Journal:  PLoS Pathog       Date:  2012-03-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.